Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome in Relapsed Cutaneous T Cell Lymphomas
NCT02597153Phase 2Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2015
- Primary completion
- Oct 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone in cutaneous T-cell lymphoma (CTCL), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Objective Response Rate at 6 months. Started Oct 2015; status: terminated.
02
Drugs
mitoxantrone
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02597153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597153.